Cargando…

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery with complete removal of the tumor is the primary treatment for resectable GIST and the only chance of cure. However, recurrence after surgery is common. The 2 main prognostic factors ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deshaies, Isabelle, Cherenfant, Jovenel, Gusani, Niraj J, Jiang, Yixing, Harvey, Harold A, Kimchi, Eric T, Kaifi, Jussuf T, Staveley-O’Carroll, Kevin F
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952484/ https://www.ncbi.nlm.nih.gov/pubmed/20957137 http://dx.doi.org/10.2147/TCRM.S5634

Ejemplares similares

Pleural space infections after image-guided percutaneous drainage of infected intraabdominal fluid collections: a retrospective single institution analysis
por: Avella, Diego M, et al.
Publicado: (2015)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Diagnosis and management of retroperitoneal ancient schwannomas
por: Choudry, Haroon A, et al.
Publicado: (2009)

PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2019)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

(18)F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
por: Avella, Diego M., et al.
Publicado: (2020)

Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
por: Boichuk, Sergei, et al.
Publicado: (2018)

SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib
por: Chen, Yan, et al.
Publicado: (2022)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
por: Cappello, Giovanni, et al.
Publicado: (2023)

Tumor-Cell–Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2020)

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol
por: Yang, Ming, et al.
Publicado: (2023)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction
por: Berney, Christophe R.
Publicado: (2015)

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib
por: Werewka-Maczuga, Agnieszka, et al.
Publicado: (2017)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
por: Bussabawalai, Thanaporn, et al.
Publicado: (2019)

The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005)

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
por: Joensuu, H, et al.
Publicado: (2011)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Spontaneous Non-Traumatic Mediastinal Hematoma in a Patient on Imatinib Therapy for a Gastrointestinal Stromal Tumor (GIST)
por: Aziz, Rida, et al.
Publicado: (2023)

Minimally Invasive Surgery in Gastrointestinal Cancer: Benefits, Challenges, and Solutions for Underutilization
por: Hamed, Osama H., et al.
Publicado: (2014)

Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2016)

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
por: Bümming, P, et al.
Publicado: (2003)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
por: Vassos, Nikolaos, et al.
Publicado: (2021)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6vvs9rc6hodujdve894l5cbrv5